Amorphical has performed two initial clinical studies in Meir4 and Hadassah5 hospitals. Both studies included terminal patients who had exhausted every available treatment option and had an estimated life expectancy of 1-3 months. Those patients were receiving no anti-cancer treatment, only palliative care to improve their quality of life. They were treated with sublingual ACC powder combined with ACC inhalation. Out of the 15 patients recruited in the two hospitals, 2 demonstrated a significant clinical improvement.
Study findings:
An 81-year-old male with advanced prostate cancer showed clinical remission, and a 74-year-old female with advanced colorectal cancer and metastases in the lungs demonstrated significant clinical improvement and returned to active life. The clinical improvement is manifested by increased blood oxidation and significant reduction of pains.
To conclude, 2 out of the 15 terminally-ill patients recruited for the studies in both sites have survived for over 2 years (as of April 2021). The study in Hadassah hospital is still open.